ストックスクリーナーアプリを入手
13.44
0.26%
0.03
Design Therapeutics Inc (DSGN) 最新ニュース
Design Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Scott Coop
Design Therapeutics Set For Multiple Clinical Trial Catalysts In H2 2026 - RTTNews
Oppenheimer Raises Price Target on Design Therapeutics to $21 From $18, Keeps Outperform Rating - marketscreener.com
Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $21 - Moomoo
Design Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Design Therapeutics (DSGN) price target increased by 12.82% to 14.96 - MSN
Design Therapeutics (NASDAQ:DSGN) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Design Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:DSGN) 2026-04-30 - Seeking Alpha
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Transcript : Design Therapeutics, Inc., Q1 2026 Earnings Call, Apr 28, 2026 - marketscreener.com
Design Therapeutics Q2 2026 slides: multiple data readouts set for 2H By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Design Therapeutics (NASDAQ:DSGN) Reaches New 1-Year High Following Earnings Beat - MarketBeat
Small-cap healthcare stocks with A+ grade EPS revisions ahead of earnings - MSN
Design Therapeutics (DSGN) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Design Therapeutics Q2 2026 slides: multiple data readouts set for 2H - Investing.com Australia
Design Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Design Therapeutics beats Q1 2026 EPS expectations - Investing.com India
Earnings call transcript: Design Therapeutics beats Q1 2026 EPS expectations By Investing.com - Investing.com South Africa
Design Therapeutics 1Q Loss/Shr 29c >DSGN - Moomoo
Design Therapeutics (NASDAQ: DSGN) Q1 loss, $223M cash and GeneTAC pipeline updates - Stock Titan
Design Therapeutics Reports Q1 2026 Results and Pipeline Progress - TipRanks
Design Therapeutics (NASDAQ:DSGN) Posts Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates - The Manila Times
Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cash runway into 2029 as Design Therapeutics (NASDAQ: DSGN) advances trials - Stock Titan
$222.8M gives Design Therapeutics funding into 2029 as trials advance - Stock Titan
This Biotech Stock Is Down 65%. How a Cancer Trial Was Ruined by Its Own Design. - Barron's
Fathom Therapeutics, Formerly Atommap, Raises $47 Million in Oversubscribed Series A Financing to Translate Physics and AI-Enabled Small Molecule Design into Next-Generation Medicines - PR Newswire
Friedreich's Ataxia Pipeline Enters a Transformative Era with - openPR.com
Friedreich’s Ataxia Pipeline Enters a Transformative Era with 20+ Therapies and Strong Clinical Momentum from Larimar Therapeutics, Minoryx Therapeutics, and Design Therapeutics | DelveInsight - Barchart
Design Therapeutics (DSGN) details 2026 annual meeting, director vote and auditor ratification - Stock Titan
Design Therapeutics (NASDAQ:DSGN) Sets New 52-Week HighStill a Buy? - MarketBeat
Episodic Ataxia Treatment Market Overview, Current Trends, and Key Player Analysis - openPR.com
Design Thera (DSGN) Stock Continuous Quote (Smart Money Flows) 2026-04-15Top Analyst Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Design Therapeutics (NASDAQ:DSGN) Reaches New 12-Month HighShould You Buy? - MarketBeat
Aug Movers: Can Design Therapeutics Inc expand its profit margins2026 Breakouts & Technical Entry and Exit Alerts - baoquankhu1.vn
We Think Design Therapeutics (NASDAQ:DSGN) Can Afford To Drive Business Growth - Yahoo Finance
FOMO Trade: Can Design Therapeutics Inc navigate macro headwinds2026 Price Action Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Astellas Licenses Dyno Therapeutics’ AI-Designed AAV Capsid, Advancing Gene Delivery for Muscle Disorders - BioPharm International
Small-cap healthcare stocks with A+ grade EPS revisions ahead of earnings (XLV:NYSEARCA) - Seeking Alpha
US Market Wrap: What is the long term forecast for Design Therapeutics Inc stock2026 Volume Leaders & Proven Capital Preservation Methods - baoquankhu1.vn
Is Design Thera (DSGN) Stock at a Peak | Price at $12.50, Down 1.34%Growth Picks - Cổng thông tin điện tử Tỉnh Sơn La
DSGN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Dyno Therapeutics Announces Capsid License Exercised by Astellas for Skeletal Muscle-Targeted Gene Delivery, Validating AI-Powered Technology for Biological Sequence Design - Business Wire
Design Therapeutics (NASDAQ:DSGN) Hits New 1-Year HighWhat's Next? - MarketBeat
0.78%
3.01%
大文字化:
|
ボリューム (24 時間):